Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 76,887	$ 6,227
Prepaid expenses and other current assets	1,749	1,707
Total Current Assets	78,636	7,934
Property and equipment, net	156	174
Right of use asset	239	279
Deposits and other assets	23	23
Total Assets	79,054	8,410
Current Liabilities:
Accounts payable	621	886
Accrued expenses	854	925
Accrued employee benefits	350	868
Operating lease liability	297	287
Total Current Liabilities	2,122	2,966
Lease liability - long term	108	186
Total Liabilities	2,230	3,152
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	0	12,798
Stockholders' Equity (Deficit):
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	0	2,477
Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at March 31, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020	132	29
Additional paid-in capital	339,019	240,821
Accumulated deficit	(259,553)	(248,094)
Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)	79,598	(4,767)
Non-controlling interest	(2,774)	(2,773)
Total Stockholders' Equity (Deficit)	76,824	(7,540)
Total Liabilities and Stockholders' Equity (Deficit)	$ 79,054	$ 8,410